nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—melanoma	0.329	0.664	CbGaD
Carvedilol—VEGFA—melanoma	0.133	0.267	CbGaD
Carvedilol—CYP1A1—Dacarbazine—melanoma	0.0368	0.182	CbGbCtD
Carvedilol—ABCB1—melanoma	0.034	0.0686	CbGaD
Carvedilol—CYP2E1—Dacarbazine—melanoma	0.0284	0.14	CbGbCtD
Carvedilol—CYP1A2—Carmustine—melanoma	0.0271	0.134	CbGbCtD
Carvedilol—CYP1A2—Vemurafenib—melanoma	0.0215	0.106	CbGbCtD
Carvedilol—CYP3A4—Temozolomide—melanoma	0.0205	0.101	CbGbCtD
Carvedilol—CYP2D6—Vemurafenib—melanoma	0.0177	0.0873	CbGbCtD
Carvedilol—CYP1A2—Dacarbazine—melanoma	0.0164	0.0812	CbGbCtD
Carvedilol—ABCB1—Dactinomycin—melanoma	0.0125	0.0616	CbGbCtD
Carvedilol—CYP3A4—Vemurafenib—melanoma	0.0112	0.0555	CbGbCtD
Carvedilol—ABCB1—Docetaxel—melanoma	0.00644	0.0318	CbGbCtD
Carvedilol—SELE—umbilical vein—melanoma	0.00494	0.0719	CbGeAlD
Carvedilol—VCAM1—umbilical vein—melanoma	0.00455	0.0661	CbGeAlD
Carvedilol—CYP3A4—Docetaxel—melanoma	0.00386	0.019	CbGbCtD
Carvedilol—NPPB—blood vessel—melanoma	0.0032	0.0465	CbGeAlD
Carvedilol—GJA1—skin epidermis—melanoma	0.00277	0.0403	CbGeAlD
Carvedilol—SELE—endothelium—melanoma	0.00234	0.0341	CbGeAlD
Carvedilol—SELE—blood vessel—melanoma	0.00216	0.0314	CbGeAlD
Carvedilol—VCAM1—endothelium—melanoma	0.00215	0.0314	CbGeAlD
Carvedilol—HIF1A—endothelium—melanoma	0.00207	0.0302	CbGeAlD
Carvedilol—HIF1A—hair follicle—melanoma	0.00204	0.0297	CbGeAlD
Carvedilol—GJA1—endothelium—melanoma	0.00201	0.0293	CbGeAlD
Carvedilol—VCAM1—blood vessel—melanoma	0.00199	0.0289	CbGeAlD
Carvedilol—GJA1—hair follicle—melanoma	0.00198	0.0288	CbGeAlD
Carvedilol—HIF1A—blood vessel—melanoma	0.00191	0.0278	CbGeAlD
Carvedilol—GJA1—blood vessel—melanoma	0.00185	0.027	CbGeAlD
Carvedilol—VCAM1—neck—melanoma	0.00142	0.0207	CbGeAlD
Carvedilol—HIF1A—neck—melanoma	0.00137	0.0199	CbGeAlD
Carvedilol—GJA1—neck—melanoma	0.00133	0.0193	CbGeAlD
Carvedilol—NDUFC2—neck—melanoma	0.00115	0.0168	CbGeAlD
Carvedilol—VCAM1—eye—melanoma	0.00106	0.0154	CbGeAlD
Carvedilol—VCAM1—retina—melanoma	0.00105	0.0152	CbGeAlD
Carvedilol—HIF1A—eye—melanoma	0.00102	0.0148	CbGeAlD
Carvedilol—HIF1A—retina—melanoma	0.00101	0.0147	CbGeAlD
Carvedilol—SELE—skin of body—melanoma	0.001	0.0146	CbGeAlD
Carvedilol—GJA1—eye—melanoma	0.000987	0.0144	CbGeAlD
Carvedilol—GJA1—retina—melanoma	0.000978	0.0142	CbGeAlD
Carvedilol—NPPB—head—melanoma	0.000966	0.0141	CbGeAlD
Carvedilol—SELE—mammalian vulva—melanoma	0.000912	0.0133	CbGeAlD
Carvedilol—HIF1A—skin of body—melanoma	0.000885	0.0129	CbGeAlD
Carvedilol—NDUFC2—eye—melanoma	0.000859	0.0125	CbGeAlD
Carvedilol—GJA1—skin of body—melanoma	0.000859	0.0125	CbGeAlD
Carvedilol—NDUFC2—retina—melanoma	0.000851	0.0124	CbGeAlD
Carvedilol—VCAM1—mammalian vulva—melanoma	0.000839	0.0122	CbGeAlD
Carvedilol—HIF1A—mammalian vulva—melanoma	0.000807	0.0117	CbGeAlD
Carvedilol—GJA1—mammalian vulva—melanoma	0.000783	0.0114	CbGeAlD
Carvedilol—NDUFC2—mammalian vulva—melanoma	0.000682	0.00992	CbGeAlD
Carvedilol—CYP1A1—skin epidermis—melanoma	0.00067	0.00975	CbGeAlD
Carvedilol—SELE—head—melanoma	0.000653	0.0095	CbGeAlD
Carvedilol—VEGFA—mammalian vulva—melanoma	0.000618	0.009	CbGeAlD
Carvedilol—VCAM1—head—melanoma	0.0006	0.00873	CbGeAlD
Carvedilol—HIF1A—head—melanoma	0.000578	0.0084	CbGeAlD
Carvedilol—GJA1—head—melanoma	0.00056	0.00815	CbGeAlD
Carvedilol—XDH—mammalian vulva—melanoma	0.00055	0.00801	CbGeAlD
Carvedilol—NDUFC2—head—melanoma	0.000488	0.0071	CbGeAlD
Carvedilol—SELE—lymph node—melanoma	0.000457	0.00665	CbGeAlD
Carvedilol—PTGS1—endothelium—melanoma	0.000427	0.00621	CbGeAlD
Carvedilol—VCAM1—lymph node—melanoma	0.00042	0.00612	CbGeAlD
Carvedilol—HIF1A—lymph node—melanoma	0.000404	0.00588	CbGeAlD
Carvedilol—PTGS1—blood vessel—melanoma	0.000394	0.00573	CbGeAlD
Carvedilol—GJA1—lymph node—melanoma	0.000392	0.00571	CbGeAlD
Carvedilol—NDUFC2—lymph node—melanoma	0.000342	0.00497	CbGeAlD
Carvedilol—VEGFA—lymph node—melanoma	0.00031	0.00451	CbGeAlD
Carvedilol—ADRA1B—head—melanoma	0.000295	0.0043	CbGeAlD
Carvedilol—ADRA1D—head—melanoma	0.000289	0.00421	CbGeAlD
Carvedilol—ABCB1—blood vessel—melanoma	0.000233	0.00339	CbGeAlD
Carvedilol—ADRA2C—mammalian vulva—melanoma	0.000221	0.00322	CbGeAlD
Carvedilol—ADRB1—head—melanoma	0.00021	0.00305	CbGeAlD
Carvedilol—CYP1A1—skin of body—melanoma	0.000208	0.00302	CbGeAlD
Carvedilol—CYP1A1—mammalian vulva—melanoma	0.000189	0.00275	CbGeAlD
Carvedilol—PTGS1—skin of body—melanoma	0.000182	0.00265	CbGeAlD
Carvedilol—Oedema peripheral—Temozolomide—melanoma	0.000181	0.00217	CcSEcCtD
Carvedilol—Cardiac failure—Docetaxel—melanoma	0.000181	0.00217	CcSEcCtD
Carvedilol—Pruritus—Vemurafenib—melanoma	0.000181	0.00217	CcSEcCtD
Carvedilol—Urethral disorder—Temozolomide—melanoma	0.000181	0.00216	CcSEcCtD
Carvedilol—Alopecia—Dactinomycin—melanoma	0.00018	0.00215	CcSEcCtD
Carvedilol—Hyponatraemia—Docetaxel—melanoma	0.000178	0.00213	CcSEcCtD
Carvedilol—Visual impairment—Temozolomide—melanoma	0.000178	0.00212	CcSEcCtD
Carvedilol—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000177	0.00212	CcSEcCtD
Carvedilol—Pain in extremity—Docetaxel—melanoma	0.000177	0.00212	CcSEcCtD
Carvedilol—ADRA2A—mammalian vulva—melanoma	0.000176	0.00257	CbGeAlD
Carvedilol—Ill-defined disorder—Bleomycin—melanoma	0.000176	0.00211	CcSEcCtD
Carvedilol—Anaemia—Bleomycin—melanoma	0.000176	0.0021	CcSEcCtD
Carvedilol—Diarrhoea—Vemurafenib—melanoma	0.000175	0.0021	CcSEcCtD
Carvedilol—Migraine—Docetaxel—melanoma	0.000174	0.00209	CcSEcCtD
Carvedilol—Erythema multiforme—Temozolomide—melanoma	0.000174	0.00208	CcSEcCtD
Carvedilol—Tinnitus—Temozolomide—melanoma	0.000172	0.00205	CcSEcCtD
Carvedilol—Malaise—Bleomycin—melanoma	0.000171	0.00205	CcSEcCtD
Carvedilol—Leukopenia—Bleomycin—melanoma	0.00017	0.00204	CcSEcCtD
Carvedilol—Dizziness—Vemurafenib—melanoma	0.000169	0.00203	CcSEcCtD
Carvedilol—Alopecia—Carmustine—melanoma	0.000168	0.00202	CcSEcCtD
Carvedilol—Angiopathy—Temozolomide—melanoma	0.000167	0.002	CcSEcCtD
Carvedilol—Immune system disorder—Temozolomide—melanoma	0.000166	0.00199	CcSEcCtD
Carvedilol—PTGS1—mammalian vulva—melanoma	0.000166	0.00242	CbGeAlD
Carvedilol—Mediastinal disorder—Temozolomide—melanoma	0.000166	0.00199	CcSEcCtD
Carvedilol—ADRA1A—head—melanoma	0.000166	0.00242	CbGeAlD
Carvedilol—Malnutrition—Carmustine—melanoma	0.000166	0.00199	CcSEcCtD
Carvedilol—Cough—Bleomycin—melanoma	0.000166	0.00198	CcSEcCtD
Carvedilol—Dehydration—Docetaxel—melanoma	0.000165	0.00197	CcSEcCtD
Carvedilol—Ill-defined disorder—Dactinomycin—melanoma	0.000164	0.00197	CcSEcCtD
Carvedilol—Anaemia—Dactinomycin—melanoma	0.000164	0.00196	CcSEcCtD
Carvedilol—Vomiting—Vemurafenib—melanoma	0.000163	0.00195	CcSEcCtD
Carvedilol—Alopecia—Temozolomide—melanoma	0.000163	0.00195	CcSEcCtD
Carvedilol—Chest pain—Bleomycin—melanoma	0.000162	0.00194	CcSEcCtD
Carvedilol—Myalgia—Bleomycin—melanoma	0.000162	0.00194	CcSEcCtD
Carvedilol—Orthostatic hypotension—Docetaxel—melanoma	0.000162	0.00193	CcSEcCtD
Carvedilol—Rash—Vemurafenib—melanoma	0.000161	0.00193	CcSEcCtD
Carvedilol—Dermatitis—Vemurafenib—melanoma	0.000161	0.00193	CcSEcCtD
Carvedilol—Back pain—Carmustine—melanoma	0.000161	0.00192	CcSEcCtD
Carvedilol—Headache—Vemurafenib—melanoma	0.00016	0.00192	CcSEcCtD
Carvedilol—Malnutrition—Temozolomide—melanoma	0.00016	0.00192	CcSEcCtD
Carvedilol—KCNH2—head—melanoma	0.00016	0.00233	CbGeAlD
Carvedilol—Discomfort—Bleomycin—melanoma	0.00016	0.00191	CcSEcCtD
Carvedilol—Malaise—Dactinomycin—melanoma	0.00016	0.00191	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000159	0.00191	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000159	0.00191	CcSEcCtD
Carvedilol—Cramp muscle—Docetaxel—melanoma	0.000159	0.00191	CcSEcCtD
Carvedilol—Leukopenia—Dactinomycin—melanoma	0.000159	0.0019	CcSEcCtD
Carvedilol—Nasopharyngitis—Docetaxel—melanoma	0.000158	0.00189	CcSEcCtD
Carvedilol—ADRA2C—head—melanoma	0.000158	0.0023	CbGeAlD
Carvedilol—Confusional state—Bleomycin—melanoma	0.000156	0.00187	CcSEcCtD
Carvedilol—Vision blurred—Carmustine—melanoma	0.000156	0.00187	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Docetaxel—melanoma	0.000156	0.00187	CcSEcCtD
Carvedilol—Oedema—Bleomycin—melanoma	0.000155	0.00186	CcSEcCtD
Carvedilol—Anaphylactic shock—Bleomycin—melanoma	0.000155	0.00186	CcSEcCtD
Carvedilol—Back pain—Temozolomide—melanoma	0.000155	0.00186	CcSEcCtD
Carvedilol—Infection—Bleomycin—melanoma	0.000154	0.00184	CcSEcCtD
Carvedilol—Anaemia—Carmustine—melanoma	0.000153	0.00183	CcSEcCtD
Carvedilol—Nausea—Vemurafenib—melanoma	0.000152	0.00182	CcSEcCtD
Carvedilol—Thrombocytopenia—Bleomycin—melanoma	0.000152	0.00182	CcSEcCtD
Carvedilol—Vision blurred—Temozolomide—melanoma	0.000151	0.00181	CcSEcCtD
Carvedilol—Myalgia—Dactinomycin—melanoma	0.000151	0.00181	CcSEcCtD
Carvedilol—Bronchospasm—Docetaxel—melanoma	0.000151	0.0018	CcSEcCtD
Carvedilol—Discomfort—Dactinomycin—melanoma	0.000149	0.00178	CcSEcCtD
Carvedilol—Angina pectoris—Docetaxel—melanoma	0.000149	0.00178	CcSEcCtD
Carvedilol—Ill-defined disorder—Temozolomide—melanoma	0.000149	0.00178	CcSEcCtD
Carvedilol—Leukopenia—Carmustine—melanoma	0.000149	0.00178	CcSEcCtD
Carvedilol—Anaemia—Temozolomide—melanoma	0.000148	0.00177	CcSEcCtD
Carvedilol—Anorexia—Bleomycin—melanoma	0.000148	0.00177	CcSEcCtD
Carvedilol—Angioedema—Temozolomide—melanoma	0.000147	0.00175	CcSEcCtD
Carvedilol—Pancytopenia—Docetaxel—melanoma	0.000145	0.00174	CcSEcCtD
Carvedilol—Hypotension—Bleomycin—melanoma	0.000145	0.00173	CcSEcCtD
Carvedilol—Oedema—Dactinomycin—melanoma	0.000145	0.00173	CcSEcCtD
Carvedilol—Malaise—Temozolomide—melanoma	0.000145	0.00173	CcSEcCtD
Carvedilol—Vertigo—Temozolomide—melanoma	0.000144	0.00172	CcSEcCtD
Carvedilol—Convulsion—Carmustine—melanoma	0.000144	0.00172	CcSEcCtD
Carvedilol—Infection—Dactinomycin—melanoma	0.000144	0.00172	CcSEcCtD
Carvedilol—Leukopenia—Temozolomide—melanoma	0.000144	0.00172	CcSEcCtD
Carvedilol—Hypertension—Carmustine—melanoma	0.000143	0.00171	CcSEcCtD
Carvedilol—Palpitations—Temozolomide—melanoma	0.000142	0.0017	CcSEcCtD
Carvedilol—Thrombocytopenia—Dactinomycin—melanoma	0.000142	0.00169	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Bleomycin—melanoma	0.000141	0.00169	CcSEcCtD
Carvedilol—Myalgia—Carmustine—melanoma	0.000141	0.00169	CcSEcCtD
Carvedilol—Chest pain—Carmustine—melanoma	0.000141	0.00169	CcSEcCtD
Carvedilol—Cough—Temozolomide—melanoma	0.00014	0.00167	CcSEcCtD
Carvedilol—Paraesthesia—Bleomycin—melanoma	0.000139	0.00167	CcSEcCtD
Carvedilol—Weight increased—Docetaxel—melanoma	0.000139	0.00167	CcSEcCtD
Carvedilol—Convulsion—Temozolomide—melanoma	0.000139	0.00166	CcSEcCtD
Carvedilol—Weight decreased—Docetaxel—melanoma	0.000138	0.00166	CcSEcCtD
Carvedilol—Hypertension—Temozolomide—melanoma	0.000138	0.00166	CcSEcCtD
Carvedilol—Dyspnoea—Bleomycin—melanoma	0.000138	0.00165	CcSEcCtD
Carvedilol—Anorexia—Dactinomycin—melanoma	0.000138	0.00165	CcSEcCtD
Carvedilol—Pneumonia—Docetaxel—melanoma	0.000137	0.00164	CcSEcCtD
Carvedilol—Confusional state—Carmustine—melanoma	0.000137	0.00163	CcSEcCtD
Carvedilol—Myalgia—Temozolomide—melanoma	0.000137	0.00163	CcSEcCtD
Carvedilol—Arthralgia—Temozolomide—melanoma	0.000137	0.00163	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000136	0.00162	CcSEcCtD
Carvedilol—Oedema—Carmustine—melanoma	0.000135	0.00162	CcSEcCtD
Carvedilol—CYP1A1—head—melanoma	0.000135	0.00197	CbGeAlD
Carvedilol—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000135	0.00162	CcSEcCtD
Carvedilol—Discomfort—Temozolomide—melanoma	0.000135	0.00161	CcSEcCtD
Carvedilol—Decreased appetite—Bleomycin—melanoma	0.000135	0.00161	CcSEcCtD
Carvedilol—Infection—Carmustine—melanoma	0.000135	0.00161	CcSEcCtD
Carvedilol—Acute coronary syndrome—Docetaxel—melanoma	0.000135	0.00161	CcSEcCtD
Carvedilol—Renal failure—Docetaxel—melanoma	0.000134	0.0016	CcSEcCtD
Carvedilol—Myocardial infarction—Docetaxel—melanoma	0.000134	0.0016	CcSEcCtD
Carvedilol—Dry mouth—Temozolomide—melanoma	0.000134	0.0016	CcSEcCtD
Carvedilol—Pain—Bleomycin—melanoma	0.000133	0.00159	CcSEcCtD
Carvedilol—Thrombocytopenia—Carmustine—melanoma	0.000133	0.00159	CcSEcCtD
Carvedilol—Tachycardia—Carmustine—melanoma	0.000132	0.00158	CcSEcCtD
Carvedilol—Confusional state—Temozolomide—melanoma	0.000132	0.00158	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000132	0.00158	CcSEcCtD
Carvedilol—Oedema—Temozolomide—melanoma	0.000131	0.00157	CcSEcCtD
Carvedilol—Anaphylactic shock—Temozolomide—melanoma	0.000131	0.00157	CcSEcCtD
Carvedilol—Infection—Temozolomide—melanoma	0.00013	0.00156	CcSEcCtD
Carvedilol—Anorexia—Carmustine—melanoma	0.000129	0.00154	CcSEcCtD
Carvedilol—Thrombocytopenia—Temozolomide—melanoma	0.000128	0.00153	CcSEcCtD
Carvedilol—Feeling abnormal—Bleomycin—melanoma	0.000128	0.00153	CcSEcCtD
Carvedilol—Skin disorder—Temozolomide—melanoma	0.000127	0.00152	CcSEcCtD
Carvedilol—Hypotension—Carmustine—melanoma	0.000127	0.00151	CcSEcCtD
Carvedilol—Hyperhidrosis—Temozolomide—melanoma	0.000127	0.00151	CcSEcCtD
Carvedilol—ADRA2A—head—melanoma	0.000126	0.00184	CbGeAlD
Carvedilol—Decreased appetite—Dactinomycin—melanoma	0.000126	0.0015	CcSEcCtD
Carvedilol—Fatigue—Dactinomycin—melanoma	0.000125	0.00149	CcSEcCtD
Carvedilol—Anorexia—Temozolomide—melanoma	0.000125	0.00149	CcSEcCtD
Carvedilol—Pain—Dactinomycin—melanoma	0.000124	0.00148	CcSEcCtD
Carvedilol—CYP2E1—head—melanoma	0.000123	0.0018	CbGeAlD
Carvedilol—Musculoskeletal discomfort—Carmustine—melanoma	0.000123	0.00148	CcSEcCtD
Carvedilol—Urticaria—Bleomycin—melanoma	0.000123	0.00147	CcSEcCtD
Carvedilol—Haemoglobin—Docetaxel—melanoma	0.000123	0.00147	CcSEcCtD
Carvedilol—Rhinitis—Docetaxel—melanoma	0.000123	0.00147	CcSEcCtD
Carvedilol—ABCB1—retina—melanoma	0.000123	0.00179	CbGeAlD
Carvedilol—Body temperature increased—Bleomycin—melanoma	0.000123	0.00147	CcSEcCtD
Carvedilol—Haemorrhage—Docetaxel—melanoma	0.000123	0.00147	CcSEcCtD
Carvedilol—Insomnia—Carmustine—melanoma	0.000122	0.00147	CcSEcCtD
Carvedilol—Hypoaesthesia—Docetaxel—melanoma	0.000122	0.00146	CcSEcCtD
Carvedilol—Paraesthesia—Carmustine—melanoma	0.000122	0.00145	CcSEcCtD
Carvedilol—Pharyngitis—Docetaxel—melanoma	0.000122	0.00145	CcSEcCtD
Carvedilol—Urinary tract disorder—Docetaxel—melanoma	0.000121	0.00145	CcSEcCtD
Carvedilol—Dyspnoea—Carmustine—melanoma	0.000121	0.00144	CcSEcCtD
Carvedilol—Oedema peripheral—Docetaxel—melanoma	0.000121	0.00144	CcSEcCtD
Carvedilol—Somnolence—Carmustine—melanoma	0.00012	0.00144	CcSEcCtD
Carvedilol—Urethral disorder—Docetaxel—melanoma	0.00012	0.00144	CcSEcCtD
Carvedilol—Feeling abnormal—Dactinomycin—melanoma	0.000119	0.00143	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Temozolomide—melanoma	0.000119	0.00143	CcSEcCtD
Carvedilol—PTGS1—head—melanoma	0.000119	0.00173	CbGeAlD
Carvedilol—Insomnia—Temozolomide—melanoma	0.000118	0.00142	CcSEcCtD
Carvedilol—Gastrointestinal pain—Dactinomycin—melanoma	0.000118	0.00142	CcSEcCtD
Carvedilol—Visual impairment—Docetaxel—melanoma	0.000118	0.00141	CcSEcCtD
Carvedilol—Decreased appetite—Carmustine—melanoma	0.000118	0.00141	CcSEcCtD
Carvedilol—Paraesthesia—Temozolomide—melanoma	0.000118	0.00141	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Carmustine—melanoma	0.000117	0.0014	CcSEcCtD
Carvedilol—Dyspnoea—Temozolomide—melanoma	0.000117	0.0014	CcSEcCtD
Carvedilol—Somnolence—Temozolomide—melanoma	0.000116	0.00139	CcSEcCtD
Carvedilol—Erythema multiforme—Docetaxel—melanoma	0.000116	0.00139	CcSEcCtD
Carvedilol—Pain—Carmustine—melanoma	0.000116	0.00139	CcSEcCtD
Carvedilol—Constipation—Carmustine—melanoma	0.000116	0.00139	CcSEcCtD
Carvedilol—Dyspepsia—Temozolomide—melanoma	0.000115	0.00138	CcSEcCtD
Carvedilol—Body temperature increased—Dactinomycin—melanoma	0.000114	0.00137	CcSEcCtD
Carvedilol—Abdominal pain—Dactinomycin—melanoma	0.000114	0.00137	CcSEcCtD
Carvedilol—Hypersensitivity—Bleomycin—melanoma	0.000114	0.00137	CcSEcCtD
Carvedilol—Decreased appetite—Temozolomide—melanoma	0.000114	0.00136	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Temozolomide—melanoma	0.000113	0.00135	CcSEcCtD
Carvedilol—Fatigue—Temozolomide—melanoma	0.000113	0.00135	CcSEcCtD
Carvedilol—KCNH2—lymph node—melanoma	0.000112	0.00163	CbGeAlD
Carvedilol—Constipation—Temozolomide—melanoma	0.000112	0.00134	CcSEcCtD
Carvedilol—Pain—Temozolomide—melanoma	0.000112	0.00134	CcSEcCtD
Carvedilol—Feeling abnormal—Carmustine—melanoma	0.000112	0.00134	CcSEcCtD
Carvedilol—Asthenia—Bleomycin—melanoma	0.000111	0.00133	CcSEcCtD
Carvedilol—Angiopathy—Docetaxel—melanoma	0.000111	0.00133	CcSEcCtD
Carvedilol—ADRA2C—lymph node—melanoma	0.000111	0.00161	CbGeAlD
Carvedilol—Gastrointestinal pain—Carmustine—melanoma	0.000111	0.00132	CcSEcCtD
Carvedilol—Immune system disorder—Docetaxel—melanoma	0.000111	0.00132	CcSEcCtD
Carvedilol—Mediastinal disorder—Docetaxel—melanoma	0.00011	0.00132	CcSEcCtD
Carvedilol—Pruritus—Bleomycin—melanoma	0.00011	0.00131	CcSEcCtD
Carvedilol—Alopecia—Docetaxel—melanoma	0.000108	0.0013	CcSEcCtD
Carvedilol—Feeling abnormal—Temozolomide—melanoma	0.000108	0.00129	CcSEcCtD
Carvedilol—Abdominal pain—Carmustine—melanoma	0.000107	0.00128	CcSEcCtD
Carvedilol—Body temperature increased—Carmustine—melanoma	0.000107	0.00128	CcSEcCtD
Carvedilol—Gastrointestinal pain—Temozolomide—melanoma	0.000107	0.00128	CcSEcCtD
Carvedilol—Malnutrition—Docetaxel—melanoma	0.000107	0.00128	CcSEcCtD
Carvedilol—Hypersensitivity—Dactinomycin—melanoma	0.000107	0.00128	CcSEcCtD
Carvedilol—Urticaria—Temozolomide—melanoma	0.000104	0.00124	CcSEcCtD
Carvedilol—Asthenia—Dactinomycin—melanoma	0.000104	0.00124	CcSEcCtD
Carvedilol—Abdominal pain—Temozolomide—melanoma	0.000103	0.00124	CcSEcCtD
Carvedilol—Body temperature increased—Temozolomide—melanoma	0.000103	0.00124	CcSEcCtD
Carvedilol—Back pain—Docetaxel—melanoma	0.000103	0.00123	CcSEcCtD
Carvedilol—Muscle spasms—Docetaxel—melanoma	0.000103	0.00123	CcSEcCtD
Carvedilol—Hypersensitivity—Carmustine—melanoma	9.98e-05	0.00119	CcSEcCtD
Carvedilol—Diarrhoea—Dactinomycin—melanoma	9.9e-05	0.00118	CcSEcCtD
Carvedilol—Vomiting—Bleomycin—melanoma	9.86e-05	0.00118	CcSEcCtD
Carvedilol—Anaemia—Docetaxel—melanoma	9.86e-05	0.00118	CcSEcCtD
Carvedilol—ABCB1—mammalian vulva—melanoma	9.83e-05	0.00143	CbGeAlD
Carvedilol—Rash—Bleomycin—melanoma	9.78e-05	0.00117	CcSEcCtD
Carvedilol—CYP2D6—head—melanoma	9.78e-05	0.00142	CbGeAlD
Carvedilol—Dermatitis—Bleomycin—melanoma	9.77e-05	0.00117	CcSEcCtD
Carvedilol—Asthenia—Carmustine—melanoma	9.72e-05	0.00116	CcSEcCtD
Carvedilol—Hypersensitivity—Temozolomide—melanoma	9.64e-05	0.00115	CcSEcCtD
Carvedilol—Syncope—Docetaxel—melanoma	9.56e-05	0.00114	CcSEcCtD
Carvedilol—Leukopenia—Docetaxel—melanoma	9.55e-05	0.00114	CcSEcCtD
Carvedilol—CYP1A1—lymph node—melanoma	9.48e-05	0.00138	CbGeAlD
Carvedilol—Palpitations—Docetaxel—melanoma	9.42e-05	0.00113	CcSEcCtD
Carvedilol—Asthenia—Temozolomide—melanoma	9.39e-05	0.00112	CcSEcCtD
Carvedilol—Loss of consciousness—Docetaxel—melanoma	9.37e-05	0.00112	CcSEcCtD
Carvedilol—Cough—Docetaxel—melanoma	9.31e-05	0.00111	CcSEcCtD
Carvedilol—Diarrhoea—Carmustine—melanoma	9.27e-05	0.00111	CcSEcCtD
Carvedilol—Pruritus—Temozolomide—melanoma	9.26e-05	0.00111	CcSEcCtD
Carvedilol—Convulsion—Docetaxel—melanoma	9.24e-05	0.00111	CcSEcCtD
Carvedilol—Nausea—Bleomycin—melanoma	9.22e-05	0.0011	CcSEcCtD
Carvedilol—Hypertension—Docetaxel—melanoma	9.21e-05	0.0011	CcSEcCtD
Carvedilol—Vomiting—Dactinomycin—melanoma	9.2e-05	0.0011	CcSEcCtD
Carvedilol—Rash—Dactinomycin—melanoma	9.12e-05	0.00109	CcSEcCtD
Carvedilol—Chest pain—Docetaxel—melanoma	9.08e-05	0.00109	CcSEcCtD
Carvedilol—Arthralgia—Docetaxel—melanoma	9.08e-05	0.00109	CcSEcCtD
Carvedilol—Myalgia—Docetaxel—melanoma	9.08e-05	0.00109	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	9.02e-05	0.00108	CcSEcCtD
Carvedilol—Dizziness—Carmustine—melanoma	8.96e-05	0.00107	CcSEcCtD
Carvedilol—Diarrhoea—Temozolomide—melanoma	8.95e-05	0.00107	CcSEcCtD
Carvedilol—Dry mouth—Docetaxel—melanoma	8.88e-05	0.00106	CcSEcCtD
Carvedilol—ADRA2A—lymph node—melanoma	8.84e-05	0.00129	CbGeAlD
Carvedilol—Confusional state—Docetaxel—melanoma	8.78e-05	0.00105	CcSEcCtD
Carvedilol—Anaphylactic shock—Docetaxel—melanoma	8.7e-05	0.00104	CcSEcCtD
Carvedilol—Oedema—Docetaxel—melanoma	8.7e-05	0.00104	CcSEcCtD
Carvedilol—Dizziness—Temozolomide—melanoma	8.65e-05	0.00104	CcSEcCtD
Carvedilol—Infection—Docetaxel—melanoma	8.65e-05	0.00103	CcSEcCtD
Carvedilol—Vomiting—Carmustine—melanoma	8.61e-05	0.00103	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—melanoma	8.59e-05	0.00103	CcSEcCtD
Carvedilol—Shock—Docetaxel—melanoma	8.56e-05	0.00102	CcSEcCtD
Carvedilol—Rash—Carmustine—melanoma	8.54e-05	0.00102	CcSEcCtD
Carvedilol—Dermatitis—Carmustine—melanoma	8.53e-05	0.00102	CcSEcCtD
Carvedilol—Thrombocytopenia—Docetaxel—melanoma	8.52e-05	0.00102	CcSEcCtD
Carvedilol—Tachycardia—Docetaxel—melanoma	8.49e-05	0.00102	CcSEcCtD
Carvedilol—Headache—Carmustine—melanoma	8.48e-05	0.00101	CcSEcCtD
Carvedilol—Skin disorder—Docetaxel—melanoma	8.45e-05	0.00101	CcSEcCtD
Carvedilol—PTGS1—lymph node—melanoma	8.33e-05	0.00121	CbGeAlD
Carvedilol—Vomiting—Temozolomide—melanoma	8.32e-05	0.000995	CcSEcCtD
Carvedilol—Anorexia—Docetaxel—melanoma	8.3e-05	0.000992	CcSEcCtD
Carvedilol—Rash—Temozolomide—melanoma	8.25e-05	0.000987	CcSEcCtD
Carvedilol—Dermatitis—Temozolomide—melanoma	8.24e-05	0.000986	CcSEcCtD
Carvedilol—Headache—Temozolomide—melanoma	8.2e-05	0.000981	CcSEcCtD
Carvedilol—Hypotension—Docetaxel—melanoma	8.13e-05	0.000973	CcSEcCtD
Carvedilol—Nausea—Carmustine—melanoma	8.04e-05	0.000962	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Docetaxel—melanoma	7.93e-05	0.000949	CcSEcCtD
Carvedilol—Insomnia—Docetaxel—melanoma	7.87e-05	0.000942	CcSEcCtD
Carvedilol—Paraesthesia—Docetaxel—melanoma	7.82e-05	0.000935	CcSEcCtD
Carvedilol—Nausea—Temozolomide—melanoma	7.77e-05	0.00093	CcSEcCtD
Carvedilol—Dyspnoea—Docetaxel—melanoma	7.76e-05	0.000928	CcSEcCtD
Carvedilol—Somnolence—Docetaxel—melanoma	7.74e-05	0.000926	CcSEcCtD
Carvedilol—Dyspepsia—Docetaxel—melanoma	7.66e-05	0.000917	CcSEcCtD
Carvedilol—Decreased appetite—Docetaxel—melanoma	7.57e-05	0.000905	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Docetaxel—melanoma	7.51e-05	0.000899	CcSEcCtD
Carvedilol—Fatigue—Docetaxel—melanoma	7.5e-05	0.000898	CcSEcCtD
Carvedilol—Constipation—Docetaxel—melanoma	7.44e-05	0.00089	CcSEcCtD
Carvedilol—Pain—Docetaxel—melanoma	7.44e-05	0.00089	CcSEcCtD
Carvedilol—Feeling abnormal—Docetaxel—melanoma	7.17e-05	0.000858	CcSEcCtD
Carvedilol—Gastrointestinal pain—Docetaxel—melanoma	7.12e-05	0.000851	CcSEcCtD
Carvedilol—ABCB1—head—melanoma	7.03e-05	0.00102	CbGeAlD
Carvedilol—Body temperature increased—Docetaxel—melanoma	6.88e-05	0.000823	CcSEcCtD
Carvedilol—Abdominal pain—Docetaxel—melanoma	6.88e-05	0.000823	CcSEcCtD
Carvedilol—Hypersensitivity—Docetaxel—melanoma	6.41e-05	0.000767	CcSEcCtD
Carvedilol—Asthenia—Docetaxel—melanoma	6.24e-05	0.000747	CcSEcCtD
Carvedilol—Pruritus—Docetaxel—melanoma	6.16e-05	0.000737	CcSEcCtD
Carvedilol—Diarrhoea—Docetaxel—melanoma	5.95e-05	0.000712	CcSEcCtD
Carvedilol—Dizziness—Docetaxel—melanoma	5.76e-05	0.000689	CcSEcCtD
Carvedilol—Vomiting—Docetaxel—melanoma	5.53e-05	0.000662	CcSEcCtD
Carvedilol—Rash—Docetaxel—melanoma	5.49e-05	0.000656	CcSEcCtD
Carvedilol—Dermatitis—Docetaxel—melanoma	5.48e-05	0.000656	CcSEcCtD
Carvedilol—Headache—Docetaxel—melanoma	5.45e-05	0.000652	CcSEcCtD
Carvedilol—Nausea—Docetaxel—melanoma	5.17e-05	0.000618	CcSEcCtD
Carvedilol—ABCB1—lymph node—melanoma	4.92e-05	0.000717	CbGeAlD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—melanoma	1.04e-06	6.95e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NFKB1—melanoma	1.04e-06	6.94e-06	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—melanoma	1.03e-06	6.94e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDKN1A—melanoma	1.03e-06	6.93e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—melanoma	1.03e-06	6.91e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—melanoma	1.03e-06	6.91e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1B—melanoma	1.03e-06	6.9e-06	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	1.03e-06	6.9e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NFKB1—melanoma	1.03e-06	6.88e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CASP3—melanoma	1.02e-06	6.87e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—melanoma	1.02e-06	6.86e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—melanoma	1.02e-06	6.86e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—melanoma	1.02e-06	6.85e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDKN1A—melanoma	1.02e-06	6.84e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—melanoma	1.02e-06	6.83e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—melanoma	1.02e-06	6.83e-06	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—melanoma	1.02e-06	6.83e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—melanoma	1.02e-06	6.82e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—melanoma	1.02e-06	6.82e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—melanoma	1.01e-06	6.8e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1B1—melanoma	1.01e-06	6.8e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NFKB1—melanoma	1.01e-06	6.79e-06	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—melanoma	1.01e-06	6.77e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CASP3—melanoma	1.01e-06	6.76e-06	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—melanoma	1.01e-06	6.76e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—melanoma	1.01e-06	6.75e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—melanoma	1.01e-06	6.74e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	1.01e-06	6.74e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—melanoma	1e-06	6.72e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—melanoma	1e-06	6.71e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—melanoma	9.98e-07	6.69e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PRKCA—melanoma	9.95e-07	6.67e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGF2—melanoma	9.94e-07	6.67e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CB—melanoma	9.94e-07	6.66e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—melanoma	9.93e-07	6.66e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—melanoma	9.88e-07	6.62e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ERCC2—melanoma	9.87e-07	6.62e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—melanoma	9.87e-07	6.62e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—melanoma	9.85e-07	6.6e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—melanoma	9.82e-07	6.58e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—melanoma	9.77e-07	6.55e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK3—melanoma	9.75e-07	6.54e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CB—melanoma	9.74e-07	6.53e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—melanoma	9.72e-07	6.52e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—melanoma	9.68e-07	6.49e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1A—melanoma	9.65e-07	6.47e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—melanoma	9.63e-07	6.46e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NFKB1—melanoma	9.58e-07	6.42e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.57e-07	6.42e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—melanoma	9.53e-07	6.39e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1A—melanoma	9.5e-07	6.37e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—melanoma	9.49e-07	6.36e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—melanoma	9.48e-07	6.35e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NFKB1—melanoma	9.43e-07	6.32e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—melanoma	9.43e-07	6.32e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—melanoma	9.4e-07	6.3e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—melanoma	9.39e-07	6.3e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CB—melanoma	9.37e-07	6.28e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—melanoma	9.36e-07	6.28e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—melanoma	9.35e-07	6.27e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	9.34e-07	6.26e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—melanoma	9.31e-07	6.24e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—melanoma	9.3e-07	6.24e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—melanoma	9.3e-07	6.24e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—melanoma	9.3e-07	6.24e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—melanoma	9.28e-07	6.23e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK1—melanoma	9.28e-07	6.22e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—melanoma	9.28e-07	6.22e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—melanoma	9.28e-07	6.22e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—melanoma	9.24e-07	6.2e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—melanoma	9.22e-07	6.18e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—melanoma	9.2e-07	6.17e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—melanoma	9.2e-07	6.17e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—melanoma	9.19e-07	6.16e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—melanoma	9.17e-07	6.15e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—melanoma	9.14e-07	6.13e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—melanoma	9.12e-07	6.12e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—melanoma	9.1e-07	6.1e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—melanoma	9.08e-07	6.09e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CB—melanoma	9.05e-07	6.07e-06	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—melanoma	9.04e-07	6.06e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CASP3—melanoma	8.96e-07	6.01e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—melanoma	8.95e-07	6e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—melanoma	8.9e-07	5.97e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK3—melanoma	8.89e-07	5.96e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—melanoma	8.88e-07	5.96e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK3—melanoma	8.81e-07	5.91e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—melanoma	8.81e-07	5.91e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—melanoma	8.77e-07	5.88e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—melanoma	8.72e-07	5.85e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—melanoma	8.7e-07	5.83e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—melanoma	8.7e-07	5.83e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK3—melanoma	8.69e-07	5.83e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—melanoma	8.64e-07	5.8e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—melanoma	8.64e-07	5.79e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—melanoma	8.64e-07	5.79e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—melanoma	8.61e-07	5.77e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—melanoma	8.59e-07	5.76e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—melanoma	8.59e-07	5.76e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CD—melanoma	8.59e-07	5.76e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—melanoma	8.57e-07	5.74e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—melanoma	8.56e-07	5.74e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—melanoma	8.49e-07	5.69e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ALB—melanoma	8.48e-07	5.68e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—melanoma	8.47e-07	5.68e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—melanoma	8.47e-07	5.68e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK1—melanoma	8.46e-07	5.67e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—melanoma	8.46e-07	5.67e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—melanoma	8.46e-07	5.67e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—melanoma	8.45e-07	5.67e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1A—melanoma	8.44e-07	5.66e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—melanoma	8.42e-07	5.64e-06	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—melanoma	8.4e-07	5.63e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK1—melanoma	8.38e-07	5.62e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—melanoma	8.38e-07	5.62e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NFKB1—melanoma	8.38e-07	5.62e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCB1—melanoma	8.35e-07	5.6e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CASP3—melanoma	8.32e-07	5.58e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—melanoma	8.31e-07	5.57e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK1—melanoma	8.27e-07	5.55e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—melanoma	8.27e-07	5.55e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—melanoma	8.27e-07	5.55e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK3—melanoma	8.23e-07	5.52e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—melanoma	8.21e-07	5.51e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.18e-07	5.48e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—melanoma	8.12e-07	5.45e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—melanoma	8.11e-07	5.44e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—melanoma	8.1e-07	5.43e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—melanoma	8.1e-07	5.43e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK3—melanoma	8.1e-07	5.43e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CD—melanoma	8.09e-07	5.43e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—melanoma	8.05e-07	5.4e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—melanoma	8.02e-07	5.38e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CD—melanoma	8.02e-07	5.38e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—melanoma	8e-07	5.37e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—melanoma	7.99e-07	5.36e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ALB—melanoma	7.99e-07	5.36e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ALB—melanoma	7.92e-07	5.31e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—melanoma	7.91e-07	5.31e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—melanoma	7.87e-07	5.28e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—melanoma	7.87e-07	5.27e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1A—melanoma	7.84e-07	5.26e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK1—melanoma	7.83e-07	5.25e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—melanoma	7.83e-07	5.25e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—melanoma	7.82e-07	5.24e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—melanoma	7.81e-07	5.24e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—melanoma	7.8e-07	5.23e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—melanoma	7.79e-07	5.22e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NFKB1—melanoma	7.78e-07	5.22e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK1—melanoma	7.7e-07	5.17e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—melanoma	7.7e-07	5.16e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PRKCA—melanoma	7.68e-07	5.15e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—melanoma	7.63e-07	5.12e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ERCC2—melanoma	7.62e-07	5.11e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—melanoma	7.6e-07	5.1e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—melanoma	7.53e-07	5.05e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—melanoma	7.53e-07	5.05e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—melanoma	7.51e-07	5.04e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CB—melanoma	7.48e-07	5.02e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—melanoma	7.45e-07	5e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—melanoma	7.42e-07	4.97e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—melanoma	7.39e-07	4.96e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—melanoma	7.34e-07	4.92e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—melanoma	7.28e-07	4.88e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—melanoma	7.27e-07	4.88e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK3—melanoma	7.19e-07	4.82e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—melanoma	7.18e-07	4.81e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—melanoma	7.13e-07	4.78e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—melanoma	7.1e-07	4.76e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—melanoma	7.06e-07	4.74e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CB—melanoma	7.05e-07	4.73e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—melanoma	7.03e-07	4.72e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—melanoma	6.99e-07	4.69e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—melanoma	6.99e-07	4.69e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CB—melanoma	6.99e-07	4.69e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—melanoma	6.99e-07	4.69e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—melanoma	6.98e-07	4.68e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—melanoma	6.94e-07	4.66e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—melanoma	6.93e-07	4.65e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CD—melanoma	6.85e-07	4.6e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK1—melanoma	6.84e-07	4.59e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—melanoma	6.84e-07	4.59e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—melanoma	6.79e-07	4.55e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—melanoma	6.79e-07	4.55e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALB—melanoma	6.77e-07	4.54e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—melanoma	6.73e-07	4.51e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—melanoma	6.68e-07	4.48e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK3—melanoma	6.68e-07	4.48e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—melanoma	6.64e-07	4.45e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—melanoma	6.64e-07	4.45e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—melanoma	6.62e-07	4.44e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—melanoma	6.6e-07	4.42e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—melanoma	6.58e-07	4.41e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—melanoma	6.57e-07	4.41e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—melanoma	6.5e-07	4.36e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—melanoma	6.5e-07	4.36e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—melanoma	6.47e-07	4.34e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—melanoma	6.47e-07	4.34e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—melanoma	6.46e-07	4.33e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—melanoma	6.44e-07	4.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK1—melanoma	6.36e-07	4.26e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—melanoma	6.36e-07	4.26e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—melanoma	6.36e-07	4.26e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—melanoma	6.28e-07	4.21e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—melanoma	6.18e-07	4.15e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—melanoma	6.09e-07	4.09e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—melanoma	6.06e-07	4.06e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—melanoma	6.04e-07	4.05e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—melanoma	6.02e-07	4.04e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—melanoma	6.01e-07	4.03e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—melanoma	6e-07	4.03e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—melanoma	5.99e-07	4.02e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CB—melanoma	5.97e-07	4.01e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—melanoma	5.94e-07	3.98e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—melanoma	5.94e-07	3.98e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—melanoma	5.92e-07	3.97e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—melanoma	5.92e-07	3.97e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—melanoma	5.86e-07	3.93e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—melanoma	5.81e-07	3.89e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—melanoma	5.74e-07	3.85e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—melanoma	5.71e-07	3.83e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—melanoma	5.55e-07	3.72e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—melanoma	5.52e-07	3.7e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—melanoma	5.49e-07	3.68e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—melanoma	5.46e-07	3.66e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—melanoma	5.39e-07	3.61e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—melanoma	5.34e-07	3.58e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CD—melanoma	5.29e-07	3.55e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—melanoma	5.26e-07	3.53e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALB—melanoma	5.22e-07	3.5e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—melanoma	5.16e-07	3.46e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—melanoma	5.1e-07	3.42e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—melanoma	4.95e-07	3.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—melanoma	4.89e-07	3.28e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—melanoma	4.85e-07	3.25e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—melanoma	4.67e-07	3.13e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CB—melanoma	4.61e-07	3.09e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—melanoma	4.57e-07	3.06e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—melanoma	4.56e-07	3.06e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—melanoma	4.51e-07	3.02e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—melanoma	4.3e-07	2.88e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—melanoma	4.26e-07	2.86e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—melanoma	3.98e-07	2.67e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—melanoma	3.73e-07	2.5e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—melanoma	3.64e-07	2.44e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—melanoma	3.51e-07	2.36e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—melanoma	3.48e-07	2.33e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—melanoma	2.98e-07	2e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—melanoma	2.81e-07	1.88e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—melanoma	2.3e-07	1.54e-06	CbGpPWpGaD
